Product Information
LITHIUM CARBONATE 300 MG TAB is a generic product labeled by Hikma Pharmaceuticals USA Inc., priced at $0.1909 per EA under NDC 00054452731. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Jan 29, 1982.
Strength
300 mg/1
Manufacturer
Hikma Pharmaceuticals USA Inc.NDC
00054452731
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
LITHIUM CARBONATEApproval Type
New Drug (NDA)
FDA Application
NDA018558FDA Approved
1/29/1982
On Market Since
1/29/1982
Pharmacological Classes
Price Statistics
The NADAC for LITHIUM CARBONATE 300 MG TAB has been published 671 times since Nov 28, 2013, and over the history we have for it it has risen 17.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1909 per EA |
|---|---|
| All-time high | $0.1934 (Jul 15, 2026) |
| All-time low | $0.1194 (Aug 23, 2023) |
| 52-week high | $0.1934 |
| 52-week low | $0.1901 |
| Median price | $0.1532 |
| Average price | $0.1548 |
| Largest weekly change | -20.2% (Nov 20, 2024) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Hikma Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Lithium Carbonate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Mood Stabilizer class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LITHIUM CARBONATE 300 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for LITHIUM CARBONATE 300 MG TAB, manufactured by Hikma Pharmaceuticals USA Inc., is $0.1909 per EA (NDC 00054452731), effective Sep 30, 2026.
How has the price of LITHIUM CARBONATE 300 MG TAB changed over time?
Over the history we have for it, the NADAC for LITHIUM CARBONATE 300 MG TAB has risen 17.8%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for LITHIUM CARBONATE 300 MG TAB?
Since Nov 28, 2013, the NADAC for LITHIUM CARBONATE 300 MG TAB has ranged from a low of $0.1194 (Aug 23, 2023) to a high of $0.1934 (Jul 15, 2026), with a median of $0.1532 per EA.
Are there cheaper alternatives to LITHIUM CARBONATE 300 MG TAB?
2 manufacturers publish a NADAC-priced product with the same active ingredient and strength as LITHIUM CARBONATE 300 MG TAB in a comparable dosage form, but none are currently priced below it.
Who manufactures LITHIUM CARBONATE 300 MG TAB?
LITHIUM CARBONATE 300 MG TAB (NDC 00054452731) is labeled by Hikma Pharmaceuticals USA Inc., and CMS classifies it as a generic product.